Pfizer, Inc. reported that it has been named the American Cancer Society’s (ACS) “2024 Corporate Partner of the Year.” The award acknowledges Pfizer’s ongoing development of products that treat cancer. However, legitimate conflict of interest issues arise when non-profit disease charities become involved in corporate partnerships with pharmaceutical companies that promote therapies and market products used to treat patient populations.1
Describing the Pfizer award, Arif Kamal, MD, Chief Patient Officer at the American Cancer Society stated:
It’s my honor to present this year’s Corporate Partner of the Year Award to Pfizer. Pfizer’s support for the Change the Odds initiative reflects their strong commitment to transforming cancer care and has enabled ACS to further amplify critical programs and resources that are working to drive change in underserved communities across the country.2
In a Jan. 30, 2024 announcement on their website, Pfizer stated that it has been working for over 20 years to advance cancer treatments and develop therapies for various types of cancer. The announcement added that the company’s scientific innovation alone cannot overcome the barriers many communities face in accessing cancer screening, diagnosis, and treatment, and explained that Pfizer has partnered with patient advocates within the oncology community, such as the American Cancer Society, to push for more access to cancer screening, etc., particularly in underserved areas.3
Is Pfizer’s Financial Support of the American Cancer Society a Conflict of Interest?
Pfizer’s designation as “2024 Corporate Partner of the Year” by the ACS raises questions about the conflicts of interest that a pharmaceutical company may have when the non-profit organizations it partners with advocate for cancer care improvements and products which the corporation markets. Pfizer’s support of initiatives like the “Change the Odds” program, which aims to address disparities in cancer outcomes, is framed as part of a larger effort to increase awareness and access to cancer screenings and treatment options in underrepresented communities.4
According to the American Cancer Society’s website:
Change the Odds is an ACS initiative with sponsorship funding from Pfizer designed to bridge the gap in cancer care disparities. The initiative aims to improve health outcomes in underserved communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, and patient support and comprehensive navigation. Change the Odds will initially focus on breast and prostate cancer, with the potential to expand to additional cancer types.5
Pfizer’s financial involvement in these initiatives could be viewed as an attempt to bolster its own reputation while promoting its products used for cancer therapies, which include those for breast and prostate cancer.6
Pfizer’s Involvement in the American Cancer Society
The American Cancer Society awarded Pfizer based on the following initiatives sponsored by the pharmaceutical company, as outlined on their website:
- In February 2024, Pfizer and American Cancer Society announced the launch of Change the Odds: Uniting to Improve Cancer Outcomes™, a three-year ACS initiative sponsored by Pfizer that aims to address cancer disparities and improve health outcomes in underrepresented communities across the United States through increasing access to and awareness of cancer screening, clinical trial opportunities and patient support and navigation.
- Since 2019, ACS has participated in the Pfizer Oncology Patient Centricity Ecosystem (POPCE), a group of advocacy and professional organizations that come together to share insights, identify concrete actions and collectively move forward on solutions to problems that inadvertently create barriers for cancer patients.
- Pfizer has supported ACS initiatives to improve equity in cancer care in the U.S. and globally through funding provided by our Global Medical Grant program and the Pfizer Foundation. These grants included support for ACS’s Hope Lodges, which offer patients and caregivers a free place to stay while undergoing cancer treatment.
- Pfizer has served as a long-time member and sponsor of several ACS Roundtables, including the Breast, Cervical, Lung and Prostate Cancer Roundtables. ACS Roundtables are national coalitions of organizations dedicated to a shared vision of giving all people a fair and just opportunity to prevent and survive cancer.
- Pfizer has supported ACS’s initiative focused on raising awareness of and increasing access to biomarker testing in the United States.
- Pfizer was a founding sponsor of the ACS Get Screened program, which worked to increase cancer screening rates following the COVID-19 pandemic, and the executive leadership served on ACS’s National Screening Consortium.7
If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.
Click here to view References:1 Goodman B. When disease charities partner with drug companies, where does that leave patients (and reporters?). Association of Health Care Journalists June 4, 2013.
2 Pfizer. Pfizer Recognized as “2024 Corporate Partner of the Year” by American Cancer Society. Jan. 30, 2025.
3 Ibid.
4 Ibid.
5 American Cancer Society. Breaking Barriers in Cancer Care Disparities.
6 Pfizer. Patrick Dempsey joins efforts to “Change the Odds” against cancer.
7 Pfizer. Pfizer Recognized as “2024 Corporate Partner of the Year” by American Cancer Society. Jan. 30, 2025.
8 Responses
Big pharma wants to be 110% sure that no cures for cancer will ever see the light of day. That would destroy their poison cancer drug empire.
Bingo!
What’s that saying, those who have the solution to the crisis, created the crisis.
Food and Chemical Toxicology wrote their findings called “Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNA”
Highlighting:
☆ mRNA vaccines promote sustained synthesis of the SARS-CoV-2 spike protein.
☆ The spike protein is neurotoxic, and it impairs DNA repair mechanisms.
☆ Suppression of type I interferon responses results in impaired innate immunity.
☆ The mRNA vaccines potentially cause increased risk to infectious diseases and cancer.
not about a cure but about ‘treatment’
lifetime customers
We have to make sure Sanders and Warren get their kickbacks and donations There can not be any mentions of any alternatives which will cut into bought to you by Pfizer Profits !
Now we know for sure to never trust the cancer industry either.
Suspiciously absent from the news article; How much money?
Pfizer’s Corporate Partnership With American Cancer Society Raises Conflict of Interest Questions / You don’t say! ‘Adventures of the guy whom just started paying attention.’ That’s among my favorite comic strips.
Pfizer’s designation as “2024 Corporate Partner of the Year” by the ACS raises questions about the conflicts of interest that a pharmaceutical company may have when the non-profit organizations it partners with advocate for cancer care improvements and products which the corporation markets. / Get this man an extra cup of coffee, he’s demonstrating signs of intelligent thinking. Remarkable.
Race for the cure, that never arrives. They’re not creating cures, they’re creating customers.
An apple a day keeps the doctor away. / Under served communities / Like groups of people whom go to hospitals less? Sounds like the more intelligent group of humans. Sometimes by chance or circumstance, you just get lucky.
HYPOCRICY‼️